Related Experiment Video
Updated: Jul 5, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Aliskiren hemifumarate]
K Kappert1, T Unger, U Kintscher
1Center vor Cardiovascular Research, CCR, Institut für Pharmakologie, Charité-Universitätsmedizin Berlin, Detschland.
Deutsche Medizinische Wochenschrift (1946)
|May 10, 2008
Summary
Aliskiren, a novel renin inhibitor, effectively reduces blood pressure in hypertensive patients. Ongoing research explores its potential benefits for heart failure and diabetic nephropathy beyond blood pressure control.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Aliskiren is the first-in-class direct renin inhibitor targeting the renin-angiotensin system.
- Approved for hypertension treatment in the US (2007) and Europe (2007).
- Demonstrated effective blood pressure reduction in clinical trials.
Purpose of the Study:
- To evaluate the efficacy of aliskiren in hypertension.
- To investigate potential benefits of aliskiren in heart failure and diabetic nephropathy.
- To assess long-term morbidity and mortality benefits of aliskiren.
Main Methods:
- Clinical trials evaluating blood pressure reduction.
- Ongoing trials assessing effects on heart failure markers (NTproBNP).
- Ongoing trials assessing effects on diabetic nephropathy markers (urinary albumin/creatinine ratio).
Main Results:
- Aliskiren effectively reduces blood pressure in hypertensive patients.
- Preliminary data suggests beneficial effects in heart failure and diabetic nephropathy.
- Reduction in urinary albumin/creatinine ratio and NTproBNP observed in specific trials.
Conclusions:
- Aliskiren is an effective antihypertensive agent.
- Further long-term clinical trials are needed to determine morbidity and mortality benefits.
- Aliskiren shows promise for treating additional conditions like heart failure and diabetic nephropathy.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...